Basal
cell carcinoma is the most common form of skin cancer and the most frequently
occurring form of all cancers. Conventional treatments to remove or destroy
basal cell carcinoma are indiscriminate and also remove or destroy normal skin cells resulting in compromised cosmetic
outcomes. Consequences of these treatments include body-image issues,
anxiety, post-traumatic stress disorder, depression, and poorer quality of
social and family life. A progressive topical cream formulation, Curaderm,
containing the natural BEC glycoalkaloids, have shown to have advantages over
conventional treatments. However, comprehensive clinical features of the skin
cancer lesions during treatment with Curaderm have to date not been reported.
This report shows that using unpublished data from a large number of patients
with varying sizes, types and locations of basal cell carcinomas when treated
with Curaderm in a phase 3 trial, an initial increase in size of the lesions
occur, followed by a reverse course, leading to complete removal of the skin
cancer. The specificity and mode of action of Curaderm explains the superior
cosmetic outcomes when compared with conventional therapies.
References
[1]
Cham, B.E. and Wilson, L. (1987) HPLC of Glycoalkaloids from Solanum Sodomaeum. Planta Medica, 53, 59-62. https://doi.org/10.1055/s-2006-962621
[2]
Daunter, B. and Cham, B.E. (1990) Solasodine Glycosides. In Vitro Preferential Cytotoxicity for Human Cancer Cells. Cancer Letters, 55, 209-220.
https://doi.org/10.1016/0304-3835(90)90121-D
[3]
Cham, B.E., Gilliver, M. and Wilson, L. (1987) Antitumour Effects of Glycoalkaloids Isolated from Solanum sodomaeum. Planta Medica, 53, 34-36.
https://doi.org/10.1055/s-2006-962612
[4]
Cham, B.E. and Meares, H.M. (1987) Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man. Cancer Letters, 36, 111-118.
https://doi.org/10.1016/0304-3835(87)90081-4
[5]
Cham, B.E., Daunter, B. and Evans, R. (1991) Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides. Cancer Letters, 59, 183-192.
https://doi.org/10.1016/0304-3835(91)90140-D
[6]
Punjabi, S., Cook, I., Kersey, P., Marks, R., Finlay, A., Sharpe, G. and Cerio, R. (2000) A Double Blind, Multi-Centre Parallel Group Study of BEC-5 Cream in Basal Cell Carcinoma. European Academy of Dermatology and Venereology, 14, 47-60.
[7]
Cham, B.E. (2014) A Review of Solasodine Rhamnosides Therapy for in-Situ squamous cell carcinoma on the Penis. Journal of Advances in Medicine and Medical Research, 4, 621-631. https://doi.org/10.9734/BJMMR/2014/4677
[8]
Goldberg, L.H., Landau, J.M., Moody, M.N. and Vergilis-Kalner, I.J. (2011) Treatment of Bowen’s Disease on the Penis with Low Concentrations of a Standard Mixture of Solasodine Glycosides and Liquid Nitrogen. Dermatologic Surgery, 37, 858-861.
https://doi.org/10.1111/j.1524-4725.2011.02014.x
[9]
Chase, T., Cham, K.E. and Cham, B.E. (2020) Curaderm, the Long-Awaited Breakthrough for Basal Cell Carcinoma. International Journal of Clinical Medicine, 11, 579-604. https://doi.org/10.4236/ijcm.2020.1110050
[10]
Cham, A., Cham, K., Chase, T. and Cham, B.E. (2015) A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. Journal of Cancer Treatment and Research, 3, 22-27.
https://doi.org/10.11648/j.jctr.20150302.12
[11]
An, W.X., Lai, H.L., Zang, Y.Y., Liu, M.H., Lin, X.K. and Cao, S.S. (2019) Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines. Frontiers in Pharmacology, 10, Article No. 758.
https://doi.org/10.3389/fphar.2019.00758
[12]
Li, X., Zhao, Y., Wu, W.K., Liu, S., Cui, M. and Lou, H. (2011) Solamargine Induces Apoptosis with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U2OS Cells. Life Sciences, 88, 314-321.
https://doi.org/10.1016/j.lfs.2010.12.006
[13]
Al Sinani, S.S., Eltayeb, E.A., Coomber, B.L. and Adham, S.A. (2016) Solamargine Triggers Cellular Necrosis Selectively in Different Types of Human Melanoma Cancer Cells through Extrinsic Lysosomal Mitochondrial Death Pathways. Cancer Cell International, 16, Article No. 11. https://doi.org/10.1186/s12935-016-0287-4
[14]
Zang, X., Yan, Z., Xu, T., An, Z., Chen, W., Wang, X., Huang, M. and Zhu, F. (2018) SM derived from Solanum Nigrum Induces Apoptosis of Human Cholangio Carcinoma QBC939 Cells. Oncology Letters, 15, 6329-6335.
https://doi.org/10.3892/ol.2018.8171
[15]
Al Sinani, S.S.S. and Eltayeb, E.A. (2017) The Steroidal Glycoalkaloids Solamargine and Solasonine in Solanum Plants. South African Journal of Botany, 112, 253-269.
https://doi.org/10.1016/j.sajb.2017.06.002
[16]
Kalalinia, F. and Korimi-Sani, I. (2017) Anticancer Properties of Solamargine: A Systematic Review. Phytotherapy Research, 31, 858-870.
https://doi.org/10.1002/ptr.5809
[17]
Sani, I.K., Marashi, S.H. and Kalalinia, F. (2015) Solamargine Inhibits Migration and Invasion of Human Hepatocellular Carcinoma Cells through Down-Regulation of Matrix Metalloproteinases 2 and 9 Expression and Activity. Toxicology in Vitro, 29, 893-900. https://doi.org/10.1016/j.tiv.2015.03.012
[18]
Li, X., Zhao, Y., Liu, S., Cui, M. and Lou, H. (2011) Induction of Actin Disruption and Downregulation of P-Glycoprotein Expression of Solamargine in Multidrug-Resistant K562/A02 Cells. Chinese Medical Journal, 124, 2038-2044.
[19]
Cham, B.E. (2013) Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with CuradermBEC5. Journal of Cancer Therapy, 4, 588-596.
https://doi.org/10.4236/jct.2013.42076
[20]
Cham, B.E. (2020) First in Man Topical Treatment of Melanoma with Solasodine Glycosides in a Formulation Curaderm. Journal of Cancer Therapy, 11, 617-630.
https://doi.org/10.4236/jct.2020.1110052
[21]
Punjabi, S., Cook, L.J., Kersey, P., Marks, R. and Cerio, R. (2008) Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma. A Double Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study. International Journal of Dermatology, 47, 78-82.
https://doi.org/10.1111/j.1365-4632.2007.03363.x
[22]
Dobrokhotova, F.Z., Betsev, A.F. and Belysheva, T.S. (2016) The Use of Kuraderm Drug in the Treatment of Basal Cell Carcinoma of the Head and Neck. Head and Neck Tumors, 6, 22-26. https://doi.org/10.17650/2222-1468-2016-6-3-22-26
[23]
Cham, B.E. (2022) The Pharmacology of Curaderm in the Treatment of Basal Cell Carcinoma. Clinical Medical Review and Case Reports, 9, Article No. 399.
https://doi.org/10.23937/2378-3656/1410399
